首页> 外文期刊>Endocrine journal >Association of Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) C1858T gene polymorphism with susceptibility to autoimmune thyroid diseases: a meta-analysis
【24h】

Association of Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) C1858T gene polymorphism with susceptibility to autoimmune thyroid diseases: a meta-analysis

机译:蛋白质酪氨酸磷酸酶非受体22(PTPN22)C1858T基因多态性与自身免疫性甲状腺疾病易感性的关联:荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Results from studies on the association of PTPN22 C1858T polymorphism with AITD risk are conflicting, we thereby perform this meta-analysis to derive a more precise effect on this possible association. Two investigators independently searched the PubMed, Embase, Wanfang and CNKI (China National Knowledge Infrastructure) databases. A total of 11 studies with 3764 AITDs cases and 3328 controls were finally identified. Statistically significant association was observed between PTPN22 C1858T polymorphism and AITD risk based on all studies (TT vs. CC, OR=2.18, 95%CI=1.31~3.62; TC vs. CC, OR=1.50, 95%CI= 1.29~1.73; TT/TC vs. CC, OR=1.41, 95%CI=1.12~1 .78; TT vs. TC/CC, OR=2.00, 95%CI=1.21~3.33). The results of subgroup analysis showed that: (1) regarding ethnic diversity, the variant genotypes TT/TC of C1858T were associated with a significantly increased AITD risk in Caucasians (TT/TC vs. CC, OR=1.41, 95%CI=1.09~1.83) (2) regarding different countries, the statistically significantly association was observed in UK (TC vs. CC, OR=1.64, 95%CI=1.36~1.98; TT/TC vs. CC, OR=1.65, 95%CI=1.37~1.98) and other countries (including Tunisia, Russia, Poland, Japan) (TT vs. CC, OR=3.65, 95%CI=1.43~9.33; TT vs. TC/CC, OR=3.41, 95%CI= 1.34~8.65). (3) regarding the subtypes of AITDs, patients with Graves' disease (GD) had a significant higher degree of C1858T polymorphism (TT vs. CC, OR=2.35, 95%CI=1.36~4.05; TC vs. CC, OR=1.46, 95%CI=1.12~1.89; TT/TC vs. CC, OR=1.54, 95%CI=1.33~1.80; TT vs. TC/CC, OR=2.16, 95%CI=1.25~3.72), while no association was observed in patients with Hashimoto's thyroiditis (HT). No publication bias was observed. Our results demonstrated that PTPN22 C1858T polymorphism was associated with AITD risk, especially in Caucasians.
机译:关于PTPN22 C1858T多态性与AITD风险的关联的研究结果相互矛盾,因此我们进行了这项荟萃分析,以得出对该可能关联的更精确的影响。两名研究人员独立搜索了PubMed,Embase,Wanfang和CNKI(中国国家知识基础设施)数据库。最终确定了11项研究,涉及3764例AITD病例和3328例对照。根据所有研究(PT vs. CC,OR = 2.18,95%CI = 1.31〜3.62; TC vs. CC,OR = 1.50,95%CI = 1.29〜1.73),PTPN22 C1858T多态性与AITD风险之间存在统计学上的显着关联。 ; TT / TC vs. CC,OR = 1.41,95%CI = 1.12〜1.78; TT vs.TC/CC,OR=2.00,95%CI=1.21~3.33)。亚组分析结果表明:(1)就种族多样性而言,C1858T的TT / TC基因型变异与高加索人的AITD风险显着相关(TT / TC vs. CC,OR = 1.41,95%CI = 1.09) 〜1.83)(2),关于不同国家/地区,在英国观察到了统计学上显着的关联(TC与CC,OR = 1.64,95%CI = 1.36〜1.98; TT / TC与CC,OR = 1.65,95%CI = 1.37〜1.98)和其他国家/地区(包括突尼斯,俄罗斯,波兰,日本)(TT vs.CC,OR = 3.65,95%CI = 1.43〜9.33; TT vs.TC/CC,OR = 3.41,95%CI = 1.34〜8.65)。 (3)关于AITD的亚型,格雷夫斯病(GD)患者的C1858T多态性水平显着更高(TT vs.CC,OR = 2.35,95%CI = 1.36〜4.05; TC vs.CC,OR = 1.46,95%CI = 1.12〜1.89; TT / TC vs. CC,OR = 1.54,95%CI = 1.33〜1.80; TT vs.TC/CC,OR = 2.16,95%CI = 1.25〜3.72),而桥本甲状腺炎(HT)患者未发现相关性。没有观察到出版偏见。我们的结果表明,PTPN22 C1858T多态性与AITD风险有关,尤其是在白种人中。

著录项

  • 来源
    《Endocrine journal》 |2012年第5期|p.439-445|共7页
  • 作者单位

    Department of Clinical Immunological Laboratory, West China Hospital, Sichuan University, 610041, China;

    Department of Clinical Immunological Laboratory, West China Hospital, Sichuan University, 610041, China;

    Department of Liver and Vascular Surgery, West China Hospital, Sichuan University, 610041, China;

    Department of Neurosurgery, West China Hospital, Sichuan University, 610041, China;

    Department of Clinical Immunological Laboratory, West China Hospital, Sichuan University, 610041, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    protein tyrosine phosphatase nonreceptor 22; polymorphism; meta-analysis; autoimmune thyroid diseases;

    机译:蛋白质酪氨酸磷酸酶非受体22;多态性荟萃分析自身免疫性甲状腺疾病;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号